Last reviewed · How we verify
Egg-based Quadrivalent Influenza Vaccine
At a glance
| Generic name | Egg-based Quadrivalent Influenza Vaccine |
|---|---|
| Also known as | Fluarix® |
| Sponsor | ModernaTX, Inc. |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1010 in Healthy Adults (PHASE2)
- Randomized Influenza Vaccine Evaluation of Immune Response (PHASE4)
- Immunogenicity Trial of 3 Influenza Vaccines (PHASE3)
- A Study to Evaluate the Safety and Immunogenicity of a Single Dose of H1ssF-3928 mRNA-LNP in Healthy Adults (PHASE1)
- Study With Quadrivalent Recombinant Influenza Vaccine (RIV4) Compared With Egg-Based Quadrivalent Influenza Vaccine (IIV4) in Participants Aged 3 to 8 Years (PHASE3)
- Clinical Trial to Evaluate the Immunogenicity of an Adjuvanted Influenza Vaccine Among HCP (PHASE3)
- Comparison of Recombinant Influenza Vaccine Versus Standard Egg-Based Inactivated Influenza Vaccine in Adults 18-64 Years (PHASE4)
- Immunogenicity Trial of Egg- Versus Non-Egg-Based Influenza Vaccines Among HCP (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Egg-based Quadrivalent Influenza Vaccine CI brief — competitive landscape report
- Egg-based Quadrivalent Influenza Vaccine updates RSS · CI watch RSS
- ModernaTX, Inc. portfolio CI